Buscar
Repare Therapeutics Inc
RPTXAñadir a la lista de seguimiento
2.650USD
0.0000.00%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
114.24MCap. mercado
PérdidaP/E TTM
Más Datos de Repare Therapeutics Inc Compañía
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Información de Repare Therapeutics Inc
Símbolo de cotizaciónRPTX
Nombre de la empresaRepare Therapeutics Inc
Fecha de salida a bolsaJun 19, 2020
Director ejecutivoForte (Steve)
Número de empleados129
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 19
Dirección7210 Frederick-Banting, Suite 100
CiudadST-LAURENT
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalH4S 2A1
Teléfono18574127018
Sitio Webhttps://www.reparerx.com/
Símbolo de cotizaciónRPTX
Fecha de salida a bolsaJun 19, 2020
Director ejecutivoForte (Steve)
Ejecutivos de Repare Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
--
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
--
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
12.82K
-146.62%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
-100.00%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
--
-100.00%
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven H. Stein, M.D.
Dr. Steven H. Stein, M.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
--
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
--
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
12.82K
-146.62%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
-100.00%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Repare Therapeutics Inc?
Los cinco principales accionistas de Repare Therapeutics Inc son: Dr. Michael Zinda, Ph.D.
¿Cuántas instituciones poseen acciones de Repare Therapeutics Inc (RPTX)?
A fecha de 2025Q4, 116 instituciones poseen acciones de Repare Therapeutics Inc, con un valor de mercado combinado de aproximadamente 24.72M, lo que representa el 57.35% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -9601917.00.